Precision Medicine Group Welcomes New General Counsel and Chief Compliance Officer and Chief People Officer
Bethesda, Md., April 26, 2023 — Precision Medicine Group (PMG), a leading next-generation provider of drug development and commercialization services, today announced the appointments of Stacey Hanna, General Counsel and Chief Compliance Officer, and Tina Durocher-Murphy, Chief People Officer. In these roles, Stacey and Tina are responsible for all legal and compliance and human resources functions, respectively, across the enterprise. Both leaders will report directly to Mark Clein, Chief Executive Officer of Precision Medicine Group.
“As Precision Medicine Group innovates and evolves, adding senior-level talent like Tina and Stacey contributes significantly to scaling people, process, and culture for our next phase of growth,” said Clein. “Stacey and Tina are experienced leaders who have proven track records to ensure that our people and processes are well connected to and supported for our growth trajectory.”
On Demand: Cell and Gene Therapies – How High Can Prices Go?
Join our experts on April 26, 2023 at 9AM EST as we dive into a powerful 30 minute webinar followed by live Q&A.
This ON24 webinar will discuss how cell and gene therapies can be justifiably priced at different levels. We will explore just how high they can extend and also how we can collectively ensure that patients can access these innovations when they are needed. This discussion will be led by David Carr: Senior Director, Global Pricing and Market Access (PRECISIONadvisors), Richard Macaulay: SVP, Global Pricing and Market Access (PRECISIONadvisors).
Precision Value & Health Acquires Makara Health, Expanding the Company’s Footprint and Communications Capabilities in Europe
Bethesda, Md., April 12, 2023 — Precision Value & Health, the industry leader in delivering complementary, integrated and specialized capabilities across the commercialization continuum, today announced that it has acquired Makara Health, a UK-based international healthcare communications agency. The move will expand Precision’s European footprint and reinforce the company’s market growth position with its core capabilities in Europe. Founded in 2013, Makara has capabilities in learning and development, medical and patient education, PR and brand promotion, offering its diverse roster of healthcare client companies high-quality, strategic, scientifically robust programs, as well as creative delivery solutions.
With this acquisition, Makara becomes part of the Precision Value & Health team. The Makara team will work closely with PRECISIONscientia, an agency dedicated to delivering medical and scientific communications that expertly interpret and translate the science of medicine.
Precision for Medicine Expands Advanced Tissue Profiling and Genomic Capabilities with new Houston Laboratory
Houston is one of seven global Precision specialty labs addressing the rising demand for rapid, comprehensive biomarker data to support the development of advanced therapies and diagnostics
HOUSTON, Tx., April 12, 2023 – Precision for Medicine, the first global biomarker-driven clinical research organization, today announced the expansion of its cell biology and genomics laboratory in Houston, TX, proliferating the company’s global biomarker capabilities and laboratory operations.
White Paper: “Preventative” Gene Therapies: Perspectives on Payer Access Challenges and Solutions
Gene therapies offer hope for patients with severe genetic diseases by providing long-term benefits and even cures. However, the challenges of evaluating the long-term benefits of these therapies from a payer perspective are considerable. This white paper by PRECISIONadvisors highlights the shift of gene therapy research into more prevalent diseases, and outlines how manufacturers and payers can co—create evidence requirements and models to optimize launch success and sustainability.